FPV MIC
Premium
- 4,318
- Australia
- GT-MIC
Oof, the tech briefing from the UK Health Security Agency gives a bleak outlook for people with just two doses of the AZ or Pfizer vaccine:
Meaghan Kall is an epidemiologist with the UKHSA and in the Twitter thread, this is the important part to call out:
So according to Dr. Kall, if you've only gotten your two doses of the AstraZeneca vaccine you're basically back to square one with Omicron. However, if you get a booster it significantly helps. I don't really know much about the AZ vaccine since it's not approved or under EUA in the US.
I'm pretty sure AstraZeneca was close to zero for the earlier strain found in South Africa too... and that's what most of the vulnerable people have had in Australia, myself included. I'll be booking in on Monday to get the booster at the first available time (17th of January by our current rules).
Edit: About AZ and Beta. A bit better than I'd remembered at least. This wasn't a very large study and not being very well versed on this I don't know how accurate it was. It seems small and the median age seems very young considering in Australia no one under 60 could have AZ for a long time and I doubt too many younger people had it once Pfizer became readily available.
''Two doses of the AstraZeneca Covid-19 vaccine were found to have only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant, according to a phase 1b-2 clinical trial published on Tuesday in the New England Journal of Medicine.
It is important to note that there were still no cases of hospitalization for severe Covid-19 or deaths observed in the study. Yet the authors did caution that the relatively young median age of participants (30 years) likely influenced the lack of severe Covid-19 cases.''
AstraZeneca Vaccine Fails To Protect Against The South African Variant, Says Study
Two doses of the AstraZeneca Covid-19 vaccine were found to have only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant, according to a phase 1b-2 clinical trial published on Tuesday in the New England Journal of Medicine.
www.forbes.com
Last edited: